Schüller, Ulrich

Dissecting the genomic complexity underlying medulloblastoma

Jones, D. T. W., Jäger, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.-J., Pugh, T. J., Hovestadt, V., Stütz, A. M., et al. (2012) · Nature

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 839

Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity

Korshunov, A., Capper, D., Reuss, D., Schrimpf, D., Ryzhova, M., Hovestadt, V., Sturm, D., Meyer, J., Jones, C., Zheludkova, O., et al. (2016) · Acta Neuropathologica

Glioma Diagnosis and TreatmentChromatin Remodeling and Cancer

Cited by 236

TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma

Remke, M., Ramaswamy, V., Peacock, J., Shih, D. J. H., Koelsche, C., Northcott, P. A., Hill, N., Cavalli, F. M. G., Kool, M., Wang, X., et al. (2013) · Acta Neuropathologica

Glioma Diagnosis and TreatmentCancer Genomics and Diagnostics

Cited by 164

Subgroup-specific immune and stromal microenvironment in medulloblastoma

Bockmayr, M., Mohme, M., Klauschen, F., Winkler, B., Budczies, J., Rutkowski, S., & Schüller, U. (2018) · OncoImmunology

Glioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers

Cited by 121

Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning

Suchorska, B., Schüller, U., Biczok, A., Lenski, M., Albert, N. L., Giese, A., Kreth, F.-W., Ertl-Wagner, B., Tonn, J.-C., & Ingrisch, M. (2019) · European Journal of Cancer

Glioma Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging

Cited by 59